Arena Stock Hits New 52-Week Low (ARNA)

Arena Pharmaceuticals (Nasdaq:ARNA) hit a new 52-week low Friday as it is currently trading at $6.91, below its previous 52-week low of $6.95 with 2.1 million shares traded as of 9:56 a.m. ET. Average volume has been 5.7 million shares over the past 30 days.
By TheStreet Wire ,

NEW YORK (

TheStreet

) --

Arena Pharmaceuticals

(Nasdaq:

ARNA

) hit a new 52-week low Friday as it is currently trading at $6.91, below its previous 52-week low of $6.95 with 2.1 million shares traded as of 9:56 a.m. ET. Average volume has been 5.7 million shares over the past 30 days.

Arena has a market cap of $1.61 billion and is part of the health care sector and drugs industry. Shares are down 17.8% year to date as of the close of trading on Wednesday.

Arena Pharmaceuticals, Inc., a biopharmaceutical company, engages in discovering, developing, and commercializing novel drugs that target G protein-coupled receptors in the therapeutic areas of cardiovascular, central nervous system, inflammatory, and metabolic diseases.

  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

TheStreet Ratings rates

Arena

as a

sell

. Among the areas we feel are negative, one of the most important has been a generally disappointing historical performance in the stock itself. You can view the full

Arena Ratings Report

.

See all

52-week low stocks

or get investment ideas from our

investment research center

.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

.

null

Loading ...